Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
Shares of Vaxart, Inc. VXRT were up 8.8% on Tuesday after the company announced that it has dosed the first subject in a phase I study, evaluating its oral tablet VXA-CoV2-1, which is a COVID-19 vaccine candidate.
In fact, the stock has skyrocketed 2088.3% so far this year against the industry’s decrease of 4.1%.
The early-stage dose-ranging study is evaluating the safety and immunogenicity of two doses (low or high) of the oral tablet VXA-CoV2-1 in healthy adult volunteers, aged between 18 years and 54 years. Enrollment in the same is expected to be completed by early next month. The first clinical data from the study is anticipated shortly in the coming weeks
Pre-clinical data had shown that the vaccine was able to generate both immune responses as well as a strong mucosal immune response against SARS-CoV-2, the virus that causes COVID-19.
Last month, the FDA cleared Vaxart’s investigational new drug (IND) application to begin the phase I study. The primary goal of the study is to investigate the safety and reactogenicity of two doses of the said vaccine. Secondary objectives include immunogenicity, duration of immune response and the occurrence of the symptomatic COVID-19.
Notably, the oral vaccine candidate is being developed leveraging the company’s proprietary oral vaccine platform VAAST.
Vaxart’s COVID-19 candidate is the only oral vaccine to be selected as part of the U.S. government’s Operation Warp Speed (OWS) program, which is a new national program to provide substantial quantities of safe, effective vaccine for the Americans by January 2021.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 38.1 million people globally and killed more than a million already.
Small biotechs like Moderna MRNA, CureVac CVAC and Novavax NVAX along with large pharma companies, namely AstraZeneca, Johnson & Johnson and Pfizer among others are actively engaged in developing a vaccine to fight the COVID-19 pandemic.
Vaxart currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis Report
Novavax, Inc. (NVAX): Free Stock Analysis Report
VAXART, INC. (VXRT): Free Stock Analysis Report
CureVac N.V. (CVAC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.